Skip to content

Homeopathic medicines for fungal infections of skin in adults

Efficacy of Individualized Bacillinum in the treatment of tinea corporis in adults: A double-blind, randomized, placebo-controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078743
Enrollment
36
Registered
2024-12-30
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Bacillinum 30CH, 200CH, 1000CH, and 10000CH, 4 medicated cane sugar globules, plus concomitant care measures for three months: Intervention is planned as administering Bacillinum 30CH,

Sponsors

D. N. De Homoeopathic Medical College & Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from tinea corporis for 3 months or more, diagnosis confirmed through KOH mount test 2. Age between 18 and 65 years 3. Patients of either sex 4. Ability to understand English and/or Bengali 5. Providing written informed consent 6. Patients using topical agents for tinea lesions will be included after a washout period of two weeks 7. Matching symptomatology of Bacillinum

Exclusion criteria

Exclusion criteria: 1. Cases with complications like lichenification and eczematisation 2. Similar-looking skin conditions, e.g., seborrheic dermatitis, pityriasis rosea, and psoriasis 3. Patients who are too sick for consultation, unable to read patient information sheets, unwilling to take part, or not giving consent to join the study 4. Vulnerable populations: unconscious, ambulatory, too sick for consultation, differently abled, terminally ill or critically ill patients, mentally incompetent people 5. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure 6. Pregnant and puerperal women, lactating mothers 7. Patients with the habit of tobacco chewing and/or smoking, alcoholism, and/or any other form(s) of substance abuse and/or dependence 8. Self-reported immunocompromised state 9. Simultaneous participation in any other clinical trial

Design outcomes

Primary

MeasureTime frame
0 to 10 numeric rating scale (NRS), measuring intensity of itchingTimepoint: day 0, 1st month, 2nd month, 3rd month

Secondary

MeasureTime frame
Skindex-29 questionnaireTimepoint: day 0, 1st month, 2nd month, 3rd month;Dermatological Life Quality Index (DLQI) questionnaireTimepoint: day 0, 1st month, 2nd month, 3rd month

Countries

India

Contacts

Public ContactAritra Roy Chowdhury

D. N. De Homoeopathic Medical College and Hospital

chandra.suman188@gmail.com9871630660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026